US FDA issues Form 483 with 9 procedural observations at Unit-VII
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Midcap 150 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
US FDA inspected Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing facility at Jedcherla, Telangana, from January 28 to February 10, 2026. A Form 483 was issued at the end with 9 observations, all described as procedural in nature. The company will respond to US FDA within stipulated timelines and stated there is no impact on financials or operations.
Minor negative — 9 procedural observations are routine but a moderate count. No financial impact claimed. Watch for final FDA classification of the inspection.